Oncology

CRISPR technology has also been successful in treating a pediatric patient with T-cell acute lymphoblastic leukemia, showing feasibility of its use for cancer immunotherapy.

Pharmacy departments can be one of the most expensive departments in a cancer center practice, but the revenue generated for its services typically far outpaces associated costs.

Cancer Moonshot Initiative launched efforts to investigate how to better support patients with cancer by providing support in the navigation of the diagnosis, treatment, and survival of cancer.

AI-enabled algorithms can also augment clinical decision making for health care professionals using real-time data analysis and decision support to treat patients more efficiently and accurately.

Through automated tools related to scheduling, prior authorization, and radiation planning tasks, there are efforts to shorten the time from diagnosis to treatment to improve patient outcomes.

Ventana PD-L1 (SP263) Assay can increase access to cemiplimab and improve patient outcomes in non-small cell lung cancer.

The vaccine targets a protein that is no longer found after lactation in normal aging tissues but is present in most triple-negative breast cancers.

Because of the complexities of cardio-oncology medication regimens, pharmacists are vital to assess drug-drug interactions using multiple resources, such as databases, case reports, FDA and National Institutes of Health guidelines, and package inserts.

Indication for abemaciclib (Verzenio; Eli Lilly and Company) in combination with endocrine therapy expanded for the adjuvant treatment of adults with hormone receptor–positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer with a high risk of recurrence.

Although pharmacokinetics and dynamics can be complex, particularly in patients with cancer, pharmacists play a key role in the various considerations and treatment decisions.

Atrial fibrillation and atherosclerotic cardiovascular disease are frequent challenges among patients with cancer.

In part 1 of this panel discussion, experts address how they define traditional versus nontraditional oncology pharmacy roles today, as well as the benefits and drawbacks of pursuing such a career path based on their experience.

At 36 months, the overall survival rate of patients with relapsed/refractory B-cell acute lymphoblastic leukemia administered brexucabtagene autoleucel was 47.1%, with a median overall survival of 26 months.

The approach was based on previous research suggesting that foods rich in carotenoids, lycopene, certain B vitamins, and omega 3 fatty acids improved fatigue in survivors of breast cancer.

The inaugural Oncology Pharmacists Connect is directed toward pharmacists practicing in oncology in multiple practice environments.

Nivolumab met its primary endpoint of recurrence-free survival, reducing the risk of recurrence or death by 58% versus placebo in patients with completely resected stage 2B or 2C melanoma.

Pembrolizumab showed statistically significant improvement in the event-free survival of patients with resectable stage 2 or 3 non-small cell lung cancer.

Therapy consists of high-dose abatacept, ruxolitinib, and proactive monitoring for respiratory muscle involvement.

The set of principles seeks to improve publication patterns to show the value of the pharmacist and how journals can strengthen pharmacy practice as a scientific discipline.

Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.

Data show continued objective response rate, overall survival, and progression-free survival benefits of nivolumab plus cabozantinib in the treatment of advanced renal cell carcinoma.

Two members of a clinical-stage authoring group discuss education programs and the alternative career path of medical writing, which can offer hybrid/virtual work-life balance opportunities.

Evaluating tasks, such as appropriate site of care and plan benefits, frees up time for pharmacists.

High-risk areas for disease progression include genitalia and the scalp.

Elranatamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody that may become the next standard of care for multiple myeloma, according to researchers.

An expert shares information on risk factors and controversies around testing.

Pharmacologic approaches can reduce the risk of chronic GVHD.

Positive data on the novel prostate cancer combination treatment was presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Olaparib with abiraterone increased survival in patients with metastatic prostate cancer compared to the current standard of care, according to a session at the ASCO Genitourinary Cancers Symposium.

The FDA approved darolutamide in 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer based improved metastasis-free survival.